Year |
Citation |
Score |
2023 |
Liu J, Xie H. BRAF Non-V600 Mutations in Metastatic Colorectal Cancer. Cancers. 15. PMID 37760573 DOI: 10.3390/cancers15184604 |
0.542 |
|
2023 |
Alem D, Yang X, Beato F, Sarcar B, Tassielli AF, Dai R, Hogenson TL, Park MA, Jiang K, Cai J, Yuan Y, Fernandez-Zapico ME, Tan AC, Fleming JB, Xie H. Translational relevance of SOS1 targeting for KRAS-mutant colorectal cancer. Molecular Carcinogenesis. PMID 37042566 DOI: 10.1002/mc.23543 |
0.547 |
|
2023 |
Liu J, Wang X, Sahin IH, Imanirad I, Felder SI, Kim RD, Xie H. Tumor Response-speed Heterogeneity as a Novel Prognostic Factor in Patients With Metastatic Colorectal Cancer. American Journal of Clinical Oncology. PMID 36606664 DOI: 10.1097/COC.0000000000000972 |
0.541 |
|
2022 |
Bian Y, Alem D, Beato F, Hogenson TL, Yang X, Jiang K, Cai J, Ma WW, Fernandez-Zapico M, Tan AC, Lawrence NJ, Fleming JB, Yuan Y, Xie H. Development of SOS1 Inhibitor-Based Degraders to Target -Mutant Colorectal Cancer. Journal of Medicinal Chemistry. PMID 36459180 DOI: 10.1021/acs.jmedchem.2c01300 |
0.542 |
|
2021 |
Xie H, Liu J, Alem Glison DM, Fleming JB. The clinical advances of proteolysis targeting chimeras in oncology. Exploration of Targeted Anti-Tumor Therapy. 2: 511-521. PMID 36046114 DOI: 10.37349/etat.2021.00061 |
0.525 |
|
2020 |
Xie H, Liu J, Yin J, Ogden JR, Mahipal A, McWilliams RR, Truty MJ, Bekaii-Saab TS, Petersen GM, Jatoi A, Hubbard JM, Ma WW. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma. The Oncologist. PMID 32663355 DOI: 10.1634/Theoncologist.2020-0086 |
0.564 |
|
2020 |
Xie H, Liu J, Ogden JR, Yin J, Jatoi A, Hubbard JM, McWilliams RR, Mahipal A, Petersen GM, Bekaii-Saab TS, Ma WW. Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma. American Journal of Clinical Oncology. PMID 32349022 DOI: 10.1097/Coc.0000000000000708 |
0.572 |
|
2019 |
Xie H, Liu J, Yadav S, Keutgen X, Hobday T, Strosberg JR, Halfdanarson T. The role of perioperative systemic therapy in localized pancreatic neuroendocrine neoplasms. Neuroendocrinology. PMID 31121586 DOI: 10.1159/000501126 |
0.589 |
|
2019 |
Xie H, Yadav S, Keutgen X, Hobday TJ, Strosberg JR, Halfdanarson TR. The role of perioperative systemic therapy in localized pancreatic neuroendocrine tumor. Journal of Clinical Oncology. 37: 322-322. DOI: 10.1200/Jco.2019.37.4_Suppl.322 |
0.318 |
|
2019 |
Xie H, Hogenson TL, Horn IP, Almada L, Marks D, Koenig A, Tolosa E, Barrett MT, Boyum JH, Mahipal A, Hubbard JM, Scheffler Hanson TJ, Yin J, Petersen GM, Revzin A, et al. Patient-derived organoid (PDO), a new personalized therapy selection tool for prompt clinical decision making in metastatic gastrointestinal (mGI) cancer patients. Journal of Clinical Oncology. 37: 3101-3101. DOI: 10.1200/Jco.2019.37.15_Suppl.3101 |
0.307 |
|
2018 |
Ma WW, Xie H, Fetterly G, Pitzonka L, Whitworth A, LeVea C, Wilton J, Mantione K, Schihl S, Dy GK, Boland P, Iyer R, Tan W, Brady W, Straubinger RM, et al. A Phase Ib Study of the FGFR/VEGFR Inhibitor Dovitinib With Gemcitabine and Capecitabine in Advanced Solid Tumor and Pancreatic Cancer Patients. American Journal of Clinical Oncology. PMID 30418178 DOI: 10.1097/Coc.0000000000000492 |
0.305 |
|
2015 |
Liu G, Lin J, Xie H, Shen B, Stocchi L, Liu X. Histomorphological features and prognosis of colitis-associated colorectal cancer in patients with primary sclerosing cholangitis. Scandinavian Journal of Gastroenterology. 1-8. PMID 26061393 DOI: 10.3109/00365521.2015.1052094 |
0.311 |
|
2015 |
Lai KK, Horvath B, Xie H, Wu X, Lewis BL, Pai RK, Plesec T, Patil DT, Gordon IO, Wang Y, Shen B, Goldblum JR, Liu X. Risk for colorectal neoplasia in patients with inflammatory bowel disease and mucosa indefinite for dysplasia. Inflammatory Bowel Diseases. 21: 378-84. PMID 25569733 DOI: 10.1097/Mib.0000000000000286 |
0.311 |
|
2013 |
Lewis B, Lin J, Wu X, Xie H, Shen B, Lai K, Manilich E, Liu X. Crohn's disease-like reaction predicts favorable prognosis in colitis-associated colorectal cancer. Inflammatory Bowel Diseases. 19: 2190-8. PMID 23917251 DOI: 10.1097/Mib.0B013E31829E13E1 |
0.334 |
|
2013 |
Xie H, Jiang W, Xiao SY, Liu X. High expression of survivin is prognostic of shorter survival but not predictive of adjuvant gemcitabine benefit in patients with resected pancreatic adenocarcinoma. The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society. 61: 148-55. PMID 23124118 DOI: 10.1369/0022155412468137 |
0.304 |
|
2013 |
Xie H, Jiang W, Jiang J, Wang Y, Kim R, Liu X, Liu X. Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma. Cancer. 119: 173-81. PMID 22736490 DOI: 10.1002/Cncr.27715 |
0.312 |
|
2012 |
Dahiya S, Xie H, Hill BT, Peereboom D, Stevens GH, Murphy E, Chao S, Suh J, Ahluwalia MS. Primary Central Nervous System Lymphoma in Elderly Patients: Clinical Outcomes and Prognosis Blood. 120: 5083-5083. DOI: 10.1182/Blood.V120.21.5083.5083 |
0.304 |
|
2011 |
Xie H, Sammis GM, Flamme EM, Kraml CM, Sorensen EJ. The catalytic asymmetric Diels-Alder reactions and post-cycloaddition reductive transpositions of 1-hydrazinodienes. Chemistry (Weinheim An Der Bergstrasse, Germany). 17: 11131-4. PMID 21898626 DOI: 10.1002/Chem.201102394 |
0.641 |
|
2005 |
Sammis GM, Flamme EM, Xie H, Ho DM, Sorensen EJ. Design, synthesis, and reactivity of 1-hydrazinodienes for use in organic synthesis. Journal of the American Chemical Society. 127: 8612-3. PMID 15954764 DOI: 10.1021/Ja052383C |
0.639 |
|
Show low-probability matches. |